Articles
-
2 days ago |
biospace.com | Heather McKenzie
When uniQure CEO Matt Kapusta speaks to patients with Huntington’s disease, he hears a sense of “deep desperation.”Currently, people with Huntington’s—who number around 30,000 in the U.S.—are only offered drugs that can manage symptoms, which include movement abnormalities and cognitive impairment, “and those drugs really don’t work very well,” Kapusta told BioSpace. “There’s no disease-modifying treatments for them.”uniQure is hoping to change that.
-
3 days ago |
biospace.com | Heather McKenzie |Jef Akst |Annalee Armstrong
> Listen on Spotify> Listen on Apple Products> Listen on Amazon Music> Listen on iHeartThe words of the week so far in biopharma are “deals” and “cancer”—or, more specifically, money being invested in cancer and other key therapeutic areas. With the American Society of Clinical Oncology’s annual conference underway in Chicago, Bristol Myers Squibb got in the PD-1/PD-L1xVEGF game, paying potentially more than $11 billion to co-develop BioNTech’s solid tumor bispecific BNT327.
-
1 week ago |
biospace.com | Dan Samorodnitsky |Heather McKenzie
Astellas Exec Speaks Out After Inking $1.5B+ Deal With Evopoint Biosciences Astellas joined a rapidly growing trend Thursday when it plunked down $130 million upfront for exclusive worldwide rights to Evopoint Biosciences’ XNW27011, an early-stage ADC designed to target the protein Claudin18.2.During a press conference at ASCO Friday morning, Astellas Chief Strategy Officer Adam Pearson addressed the deal. “I think we’re always on the lookout for great innovation,” he said.
-
1 week ago |
biospace.com | Heather McKenzie |Jef Akst |Annalee Armstrong
> Listen on Spotify> Listen on Apple Products> Listen on Amazon Music> Listen on iHeartThe name of the biopharma game this season is vaccines—and RFK Jr. wasted no time returning from Memorial Day Weekend before making news on this front, removing the COVID-19 vaccine from the list of recommended immunizations for healthy kids and pregnant women on Tuesday.
-
1 week ago |
biospace.com | Heather McKenzie
Founders and executives of Karuna Therapeutics and Naurex are back with a brand-new biotech, aiming to “build the first synapse-targeted company” for the treatment of diseases like depression and Alzheimer’s, according to CEO Derek Small, former chief executive at Naurex. Led by Small—together with former Karuna execs Steve Brannan and Anantha Shekhar and Nobel Laureate Thomas Südhof, among other prominent names—Syndeio Biosciences uncloaked itself Tuesday with $90 million in startup funds.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- Tweets
- DMs Open
RT @RWPUSA: As I told Heather McKenzie here: “There’s objective truth in science, and the extreme left and extreme right have always wanted…
RT @BowTiedBiotech: 🧠 HUGE NEWS - $AZN out of Neuro!!!! Big loss for patients….disappointing “CNS really is probably better managed by ot…
#biopharma conference season is in full swing, and our very own @JefAkst and @Slabodkin will be at hashtag#ASGCT24 in Baltimore next week. https://t.co/WgYSWHxOtb